Profile data is unavailable for this security.
About the company
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
- Revenue in USD (TTM)185.74m
- Net income in USD-130.77m
- Incorporated2020
- Employees435.00
- LocationMaravai LifeSciences Holdings Inc10770 Wateridge Circle Suite 200Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 546-0004
- Fax+1 (302) 655-5049
- Websitehttps://www.maravai.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xencor Inc | 125.58m | -91.92m | 881.53m | 260.00 | -- | 1.36 | -- | 7.02 | -1.24 | -1.24 | 1.69 | 8.84 | 0.1374 | -- | 2.79 | 482,984.60 | -10.08 | -9.90 | -11.18 | -10.89 | -- | -- | -73.37 | -51.10 | -- | -- | 0.1585 | -- | 13.65 | 0.4654 | 60.48 | -- | -25.55 | -- |
| MannKind Corp | 348.97m | 6.70m | 901.19m | 592.00 | 151.48 | -- | 47.48 | 2.58 | 0.0193 | 0.0193 | 1.12 | -0.1658 | 0.5885 | 2.45 | 6.56 | 589,469.60 | 1.13 | -7.58 | 1.44 | -9.71 | 77.80 | 70.19 | 1.92 | -14.56 | 1.50 | 1.31 | 1.09 | -- | 22.23 | 39.89 | -78.75 | -- | -0.9285 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 902.00m | 44.00 | -- | 11.63 | -- | 61.76 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 904.20m | 15.00 | -- | 14.56 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| Personalis Inc | 69.65m | -81.27m | 907.16m | 260.00 | -- | 3.40 | -- | 13.02 | -0.9088 | -0.9088 | 0.7805 | 2.55 | 0.2305 | 8.92 | 5.72 | 267,876.90 | -26.89 | -30.49 | -30.46 | -34.81 | 22.65 | 27.97 | -116.69 | -118.80 | 6.61 | -- | 0.0197 | -- | -17.69 | -2.40 | 0.0172 | -- | 6.77 | -- |
| Geron Corp | 183.88m | -83.50m | 919.23m | 258.00 | -- | 4.08 | -- | 5.00 | -0.1252 | -0.1252 | 0.2758 | 0.353 | 0.3159 | 0.0611 | 5.04 | 712,717.10 | -14.34 | -38.37 | -17.32 | -48.79 | 97.42 | -- | -45.41 | -266.14 | 3.62 | -3.55 | 0.5245 | -- | 138.83 | 273.49 | 52.17 | -- | -34.32 | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 929.27m | 111.00 | -- | 2.06 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 929.38m | 378.00 | -- | 23.44 | -- | 27.68 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| Maravai Lifesciences Holdings Inc | 185.74m | -130.77m | 948.58m | 435.00 | -- | 4.45 | -- | 5.11 | -0.9059 | -0.9059 | 1.29 | 0.8296 | 0.2088 | 3.35 | 5.80 | 426,995.40 | -25.95 | 4.29 | -36.49 | 5.56 | 18.30 | 68.51 | -124.24 | 13.71 | 5.69 | -7.54 | 0.4642 | 0.00 | -28.34 | -8.15 | 9.72 | -- | -12.34 | -- |
| GH Research PLC | 0.00 | -42.92m | 949.05m | 50.00 | -- | 3.26 | -- | -- | -0.7313 | -0.7313 | 0.00 | 4.70 | 0.00 | -- | -- | 0.00 | -17.11 | -12.39 | -17.83 | -12.66 | -- | -- | -- | -- | -- | -- | 0.002 | -- | -- | -- | -9.48 | -- | -- | -- |
| CareDx Inc | 379.81m | -21.35m | 962.87m | 761.00 | -- | 3.16 | -- | 2.54 | -0.3943 | -0.3943 | 7.09 | 5.95 | 0.84 | 5.33 | 7.08 | 499,086.70 | -4.72 | -10.84 | -5.89 | -12.94 | 67.55 | 66.23 | -5.62 | -16.52 | 2.56 | -- | 0.00 | -- | 13.79 | 14.59 | -140.64 | -- | -8.66 | -- |
| Fortrea Holdings Inc | 2.72bn | -986.20m | 979.88m | 14.30k | -- | 1.73 | -- | 0.3598 | -10.90 | -10.90 | 29.66 | 6.05 | 0.8653 | -- | 4.36 | 190,447.50 | -31.33 | -5.20 | -44.50 | -6.52 | 18.50 | 20.89 | -36.21 | -7.39 | -- | -0.2587 | 0.6514 | -- | 1.00 | 1.09 | -263.24 | -- | 0.9806 | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 983.58m | 35.00 | -- | 4.68 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 988.28m | 52.00 | -- | 3.21 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.22 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Maravai LifeSciences Holdings Inc's reporting currency: US Dollar USD
39.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 12 West Capital Management LPas of 31 Dec 2025 | 8.92m | 6.15% |
| Braidwell LPas of 31 Dec 2025 | 8.35m | 5.76% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 7.94m | 5.48% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.34m | 4.37% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 6.34m | 4.37% |
| Mackenzie Financial Corp.as of 31 Dec 2025 | 6.17m | 4.26% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 4.23m | 2.91% |
| Monaco Asset Management SAMas of 31 Dec 2025 | 3.46m | 2.39% |
| Philosophy Capital Management LLCas of 31 Dec 2025 | 3.10m | 2.14% |
| Tejara Capital Ltd.as of 31 Dec 2025 | 3.02m | 2.08% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
